I.-Subject to the adaptations mentioned in II, the provisions of Title II of Book I of this Part are applicable in New Caledonia and French Polynesia, in the wording indicated in the right-hand column of the table in I:
ARTICLES | IN THE VERSION RESULTING FROM |
---|---|
L. 1121-1 | Order no. 2022-1086 of 29 July 2022 |
L. 1121-2 | Law no. 2012-300 of 5 March 2012 |
L. 1121-3 | Order no. 2016-800 of 16 June 2016 |
L. 1121-4 | Order no. 2016-800 of 16 June 2016 |
L. 1121-5 | Law n° 2012-300 of 5 March 2012 |
L. 1121-6 | Law n° 2012-300 of 5 March 2012 |
L. 1121-7 | Law no. 2019-180 of 8 March 2019 |
L. 1121-8 |
Ordinance no. 2020-232 of 11 March 2020 in French Polynesia
Law no. 2012-300 of 5 March 2012 in New Caledonia |
L. 1121-8-1 | Order no. 2016-800 of 16 June 2016 |
L. 1121-9 | Law no. 2012-300 of 5 March 2012 |
L. 1121-10 | Law n° 2012-300 of 5 March 2012 |
L. 1121-11 |
Ordinance no. 2020-232 of 11 March 2020 in French Polynesia
Law no. 2012-300 of 5 March 2012 in New Caledonia |
L. 1121-12 | Law no. 2012-300 of 5 March 2012 |
L. 1121-13 | Order no. 2018-20 of 17 January 2018 |
L. 1121-14 | Law no. 2012-300 of 5 March 2012 |
L. 1121-15 | Order no. 2018-20 of 17 January 2018 |
L. 1121-16 | Law n° 2012-300 of 5 March 2012 |
L. 1121-16-1, with the exception of III | Law no. 2019-774 of 24 July 2019 |
L. 1121-16-2 | Law no. 2012-300 of 5 March 2012 |
L. 1121-17 | Law no. 2004-806 of 9 August 2004 |
L. 1122-1 | Order no. 2018-1125 of 12 December 2018 |
L. 1122-1-1 | Order no. 2016-800 of 16 June 2016 |
L. 1122-1-2 | Order no. 2016-800 of 16 June 2016 |
L. 112-1-3 | Order no. 2016-800 of 16 June 2016 |
L. 1122-1-4 | Order no. 2016-800 of 16 June 2016 |
L 1122-2 |
Order no. 2020-232 of 11 March 2020 in French Polynesia
Law no. 2004-806 of 9 August 2004 in New Caledonia |
L. 1123-1 | Ordinance no. 2016-800 of 16 June 2016 |
L. 1123-1-1 | Ordinance no. 2016-800 of 16 June 2016 |
L. 1123-2 | Law no. 2012-300 of 5 March 2012 |
L. 1123-3 | Order no. 2018-20 of 17 January 2018 |
L. 1123-5 | Law no. 2004-806 of 9 August 2004 |
L. 1123-6 | Law no. 2018-892 of 17 October 2018 |
L. 1123-7 | Law no. 2020-1525 of 7 December 2020 |
L. 1123-7-2 | Order no. 2016-800 of 16 June 2016 |
L. 1123-8 | Law no. 2012-300 of 5 March 2012 |
L. 1123-9 | Order no. 2016-800 of 16 June 2016 |
L. 1123-10 | Order no. 2016-800 of 16 June 2016 |
L. 1123-11 | Law no. 2012-300 of 5 March 2012 |
L. 1123-12 | Order no. 2016-800 of 16 June 2016 |
L. 1123-13 | Law no. 2004-806 of 9 August 2004 |
L. 1123-14 | Order no. 2016-800 of 16 June 2016 |
L. 1123-15 | Order no. 2022-1086 of 29 July 2022 |
L. 1123-16 | Order no. 2022-1086 of 29 July 2022 |
L. 1123-17 | Order no. 2022-1086 of 29 July 2022 |
L. 1123-18 | Order no. 2022-1086 of 29 July 2022 |
L. 1123-19 | Order no. 2022-1086 of 29 July 2022 |
L. 1123-20 | Order no. 2022-1086 of 29 July 2022 |
L. 1124-1 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-1 | Government Order no. 2022-1086 of 29 July 2022 |
L. 1125-2 | Government Order no. 2022-582 of 20 April 2022 |
L. 1125-3 | Order no. 2022-582 of 20 April 2022 |
L. 1125-4 | Order n° 2022-582 of 20 April 2022 |
L. 1125-5 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-6 | Order no. 2022-1086 of 29 July 2022 |
L 1125-7 | Government Order no. 2022-582 of 20 April 2022 |
L. 1125-8 | Order n° 2022-582 of 20 April 2022 |
L. 1125-9 | Order no. 2022-582 of 20 April 2022 |
L. 1125-10 | Order no. 2022-582 of 20 April 2022 |
L. 1125-11 | Order n° 2022-582 of 20 April 2022 |
L. 1125-12 | Order no. 2022-582 of 20 April 2022 |
L. 1125-13 | Order no. 2022-582 of 20 April 2022 |
L. 1125-14 | Order no. 2022-582 of 20 April 2022 |
L. 1125-15 with the exception of III | Order no. 2022-582 of 20 April 2022 |
L. 1125-16 | Order no. 2022-582 of 20 April 2022 |
L. 1125-17 | Order no. 2022-582 of 20 April 2022 |
L. 1125-18 | Order no. 2022-582 of 20 April 2022 |
L. 1125-19 | Order n° 2022-582 of 20 April 2022 |
L. 1125-20 | Order no. 2022-582 of 20 April 2022 |
L. 1125-21 | Government Order no. 2022-1086 of 29 July 2022 |
L. 1125-22 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-23 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-24 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-25 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-26 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-27 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-28 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-29 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-30 | Order no. 2022-1086 of 29 July 2022 |
L. 1125-31 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-1 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-2 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-3 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-4 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-5 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-6 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-7 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-8 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-9 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-10 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-11 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-12 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-13 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-14, with the exception of III | Order no. 2022-1086 of 29 July 2022 |
L. 1126-15 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-16 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-17 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-18 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-19 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-20 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-21 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-22 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-23 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-24 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-25 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-26 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-27 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-28 | Order no. 2022-1086 of 29 July 2022 |
L. 1126-29 | Order no. 2022-1086 of 29 July 2022 |
L. 1127-1 | Order no. 2022-1086 of 29 July 2022 |
L. 1127-2 | Government Order no. 2022-1086 of 29 July 2022 |
L. 1127-3 | Order no. 2022-1086 of 29 July 2022 |
L. 1127-4 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-1 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-2 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-3 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-4 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-5 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-6 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-7 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-8 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-9 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-10 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-11 | Order no. 2022-1086 of 29 July 2022 |
L. 1128-12 | Order no. 2022-1086 of 29 July 2022 |
II. – For the application in New Caledonia and French Polynesia of the provisions mentioned in I:
1° The reference: “L. 5311-1” is replaced by the reference: “L. 5541-3” ;
2° a) In Article L. 1121-1, after the words: “This person or his legal representative must be established in the European Union”, the following words are added: “, or in the Wallis and Futuna Islands or in New Caledonia or in French Polynesia”;
b) The seventh paragraph of Article L. 1121-3 is replaced by the following provisions:
By way of derogation from the provisions of the second paragraph, research involving the human person, other than that on products mentioned in Article L. 5541-3, may be carried out under the supervision of a qualified person provided that it meets the following conditions:
1° They involve products on a list drawn up by decree by the Conseil d’Etat; products for local use likely to appear on this list are proposed by the competent authority of New Caledonia or French Polynesia;
2° Entail only negligible risks and have no influence on the medical care of the person undergoing them.
c) The last paragraph of Article L. 1121-11 is replaced by the following provisions:
By way of derogation from the provisions of the second paragraph, research involving the human person, other than that relating to products mentioned in Article L. 5541-3, may be carried out without prior medical examination provided that it meets the following conditions:
1° It involves products included on a list drawn up by decree by the Conseil d’Etat; products for local use likely to appear on this list are proposed by the competent authority of New Caledonia or French Polynesia;
2° Entail only negligible risks and have no influence on the medical care of the person undergoing them.
d) In Article L. 1121-13, the words: “by the Director General of the Regional Health Agency” are replaced by the words: “by the High Commissioner of the Republic in New Caledonia or French Polynesia following the opinion of the locally competent health authority”, the words: “in an establishment mentioned in Article L. 5126-1” are replaced by the words: “in an establishment with an in-house pharmacy authorised by the competent authorities of New Caledonia or French Polynesia” and the words: “the good practices mentioned in Article L. 5121-5” are replaced by the words: “the good manufacturing practices for medicinal products laid down by the competent authorities of New Caledonia or French Polynesia”;
e) A paragraph is added to article L. 1121-15, worded as follows:
The authority responsible for health product safety in New Caledonia or French Polynesia is kept informed by the Agence nationale de sécurité du médicament et des produits de santé.
f) In Article L. 1122-1, after the words: “Where non-interventional research concerns compliance with a treatment and its performance is in response to a request from the Agence nationale de sécurité du médicament et des produits de santé, the Haute Autorité de santé or the European Medicines Agency,” the following words are added: “or the competent authority in New Caledonia or French Polynesia. ” ;
g) In Article L. 1122-2, the words “biomedical research” are replaced by the words “research involving the human person”.
3° a) A second paragraph is added to Article L. 1123-1, which reads as follows: “The competence of these committees is extended to cover the whole of the French Polynesia:
The competence of these committees is extended to New Caledonia and French Polynesia.
b) A new paragraph is added to article L. 1123-7 as follows:
“Upon request to the relevant Committee for the Protection of Individuals or the National Agency for the Safety of Medicinal and Health Products, the High Commissioner of the Republic and the competent authority in New Caledonia and French Polynesia shall have access to all relevant information relating to the research mentioned in 1°, 2° and 3° of Article L. 1121-1. “
c) In Article L. 1123-7-2, after the words: “marketing authorisation”, the following words are inserted: “by the competent authorities of New Caledonia or French Polynesia” and a final sentence is inserted into the second paragraph of Article L. 1123-11 as follows:
“In particular, it may refer to the competent local health authority any request to ensure the safety of participants in research involving the human person. “
d) In Article L. 1123-12: the reference: “L. 5311-1” is replaced by the words: “L. 5541-3 or on products authorised by the local regulations in force in New Caledonia and French Polynesia respectively”.
e) In Article L. 1123-14, 10°, after the words “other Member States”, the words “New Caledonia and French Polynesia” are inserted. “
f) The first sentence of Article L. 1123-15 is replaced by the following provisions:
“Research involving the human being which is a national defence secret within the meaning of Article 413-9 of the Criminal Code and which is carried out for protection purposes shall be conducted in accordance with the provisions of this chapter.”;
g) In Article L. 1123-17 the words: “the authority designated in Article L. 1123-12 or in II of Articles L. 1125-1 and L. 1126-1” are replaced by the words: “l’Agence nationale de sécurité du médicament et des produits de santé”
h) In Article L. 1123-18, the words: “mentioned in 1° of Article L. 1121-1” are replaced by the words: “interventional which involves an intervention on the person not justified by his usual care”;
i) In 3° of Article L. 1123-20, the words: “the request for modification of the research provided for in Article L. 1123-9” are replaced by the words: “the request for substantial modification of the research provided for in Article L. 1123-18”;
4° In IV of Article L. 1124-1, the words: “as defined” are replaced by the words: “meeting the definition provided for” and the references: “L. 5121-1-1, L. 5125-1 and L. 5126-1” are replaced by the words: “and to the pharmaceutical regulations applicable in New Caledonia or French Polynesia for medicinal products meeting the definition provided for in Articles L. 5121-1-1, L. 5125-1 and L. 5126-1. “
5° In Article L. 1125-12, the words: “by the Director General of the Regional Health Agency” are replaced by the words: “by the High Commissioner of the Republic in New Caledonia or French Polynesia after obtaining the opinion of the competent local health authority”;
6° a) For the application of Article L. 1121-1, references to Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014, references to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 and references to Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 are replaced by references to the rules applicable in mainland France under Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014, Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 and Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 ;
b) For the application of Article L. 1124-1, references to Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 are replaced by references to the rules applicable in mainland France under Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 ;
c) For the purposes of Articles L. 1125-1, L. 1125-2, L. 1125-4, L. 1125-5, L. 1125-7, L. 1125-16, L. 1125-17, L. 1125-20, L. 1125-21, L. 1125-28, L. 1125-31, references to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 are replaced by references to the rules applicable in mainland France under Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 ;
d) For the application of Articles L. 1126-1, L. 1126-2, L. 1126-4, L. 1126-6, L. 1126-15, L. 1126-16, L. 1126-19, L. 1126-20, L. 1126-27, L. 1126-29, references to Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 are replaced by references to the rules applicable in mainland France under Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 ;
e) For the purposes of Article L. 1127-3, references to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 are replaced by references to the rules applicable in mainland France under Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 ;
f) For the purposes of Articles L. 1128-1, L. 1128-3 and L. 1128-12, references to Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 are replaced by references to the rules applicable in mainland France under Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014.